Jamieson Wellness to be acquired by Kirin in C$2.5 billion transaction
Jamieson Wellness announced that it has entered into a definitive agreement to be acquired by Kirin Holdings Company for C$45.75 per share in cash, valuing the transaction at approximately C$2.5 billion on an enterprise value basis. The offer represents a 27% premium to Jamieson Wellness’ 20-day volume-weighted average share price. The transaction has been unanimously approved by Jamieson’s Board and is subject to shareholder, court and regulatory approvals. Subject to customary closing conditions, the acquisition is expected to be completed in the fourth quarter of 2026.
AstraZeneca’s Fasenra (benralizumab) approved in Canada for hypereosinophilic syndrome
Health Canada has granted a Notice of Compliance for AstraZeneca’s Fasenra (benralizumab) as an add-on to standard therapy for patients aged 12 years and older with hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. The approval was supported by the Phase III NATRON trial, in which benralizumab significantly reduced the risk of HES worsening or flare by 65% compared with placebo and delayed time to first flare. The approval provides a new treatment option for Canadians living with this rare and potentially serious disorder.
Bracco’s VUEJECT receives FDA 510(k) clearance and Health Canada authorization
Bracco announced that VUEJECT, a dedicated ultrasound contrast delivery system designed to support contrast-enhanced echocardiography, has received U.S. FDA 510(k) clearance and Health Canada authorization. The system is designed to streamline the preparation and delivery of ultrasound contrast agents during cardiac imaging procedures, supporting consistent administration and workflow efficiency. The regulatory milestones expand availability of VUEJECT in North America and strengthen Bracco’s portfolio of solutions for contrast-enhanced ultrasound and cardiovascular imaging.
Grey Matter Neurosciences selects treatment-resistant depression for inaugural clinical focus
Grey Matter Neurosciences announced that treatment-resistant depression (TRD) will be the first clinical focus for its neuromodulation platform. The company plans to initiate a pilot clinical study targeting seniors and adults living with TRD in early 2027. To support recruitment for the study and future clinical research, Grey Matter has also launched an online patient registry. The initiative marks the company’s initial step toward evaluating its neurotechnology platform in people with treatment-resistant depression and building a participant network for future research.
Roche’s Itovebi (inavolisib) now publicly funded in Québec for advanced breast cancer
Roche Canada announced that Itovebi (inavolisib) is now publicly funded in Québec through the RAMQ List of Medications for eligible adults with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation. The listing, effective June 25, 2026, follows unanimous recognition of therapeutic value by INESSS and successful negotiations with the pCPA. The decision was supported by INAVO120 results, which showed that Itovebi in combination with palbociclib and fulvestrant more than doubled median progression-free survival compared with palbociclib and fulvestrant alone.
DeltaSleep becomes Canada’s only domestic manufacturer of CPAP, APAP and BiPAP devices
DeltaSleep announced the full commercial availability of its Canadian-made Notte Series CPAP, APAP and BiPAP devices, making it the only manufacturer producing clinical-grade sleep therapy devices in Canada. The Health Canada-licensed devices are designed, assembled and serviced in Woodbridge, Ontario, and connect to a Canadian-hosted cloud platform for real-time therapy data and compliance reporting. The launch establishes a domestic supply option for sleep-related breathing disorder devices, reducing reliance on international supply chains and supporting faster response to clinical, service and supply requirements for Canadian patients and healthcare providers.
Kye Pharmaceuticals launches SLENYTO (melatonin extended-release tablets) in Canada
Kye Pharmaceuticals announced that SLENYTO (melatonin extended-release tablets) is now available across Canada by prescription for the treatment of insomnia in children and adolescents aged 2 to under 18 years with autism spectrum disorder (ASD) and/or Smith-Magenis syndrome (SMS) when sleep hygiene measures are insufficient. Health Canada granted SLENYTO a Notice of Compliance in September 2025. The pediatric extended-release formulation is designed to mimic natural nighttime melatonin secretion and provides a treatment option specifically developed and studied for this patient population.
Zomedica and Boehringer Ingelheim collaborate to expand equine endocrine diagnostic testing
Zomedica announced a strategic collaboration with Boehringer Ingelheim Animal Health to enhance the early detection, treatment, and monitoring of pituitary pars intermedia dysfunction (PPID) in horses. The collaboration integrates Zomedica’s TRUFORMA diagnostic platform into Boehringer Ingelheim’s idPPID awareness and testing program, enabling veterinarians to perform point-of-care endocrine testing using equine endogenous ACTH and insulin assays. Boehringer Ingelheim will reimburse participating veterinarians for eligible testing, while Zomedica will promote the program through its veterinary customer networks.
Light AI’s QuickScan Strep A receives Health Canada medical device license
Light AI announced that Health Canada has issued a Class II Medical Device License for QuickScan Strep A, the company’s first Software as a Medical Device (SaMD) product. The AI-powered clinical decision support software uses machine learning and digital throat images to assist healthcare professionals in assessing patients with symptoms consistent with Group A Streptococcal (GAS) pharyngitis. The license enables Light AI to advance toward commercial introduction of QuickScan Strep A in Canada and marks a key regulatory milestone as the company expands its AI-powered QuickScan platform.
